<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176891</url>
  </required_header>
  <id_info>
    <org_study_id>MT2004-09</org_study_id>
    <secondary_id>0403M57728</secondary_id>
    <nct_id>NCT00176891</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant w/Laronidase for Hurler</brief_title>
  <official_title>Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior
      to transplant and 8 weeks following transplant will result in a reduction of
      glycosaminoglycans (GAG) burden that is associated with decreased complications following
      transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive laronidase once a week intravenously for 10-12 weeks prior to
      transplant and for approximately 8 weeks after transplant. Laronidase will be given by
      intravenous infusion (IV) through a catheter and from there to your child's body's cells and
      organs to break down the glycosaminoglycans (GAG) buildup.

      Prior to starting ERT, subjects will have a complete physical examination, which includes a
      complete assessment of your child's airway and lungs. In addition to standard treatment
      evaluations and tests, which are done prior to hematopoietic stem cell transplant (HSCT),
      subjects will have the following tests: an additional teaspoon of blood for a baseline test
      for serum antibodies against laronidase, before and after the fourth dose of laronidase, the
      investigators will collect 2 teaspoons of blood for an alpha-L-iduronidase enzyme level; to
      watch for side effects to laronidase and the development of antibodies to laronidase,
      approximately 2 teaspoons of blood will be collected every 3 weeks while the subject is
      receiving laronidase ERT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Alive at One Year Post Transplant</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Requiring Ventilator Support at One Year Post Transplant</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor Engraftment</measure>
    <time_frame>Day 100 post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Grade III-IV Acute GVHD</measure>
    <time_frame>Day 100 post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Glycosaminoglycans (GAG)</measure>
    <time_frame>Prior to, During and After ERT</time_frame>
    <description>Data was not collected on this outcome measure and is not available for reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (Adverse Events) Associated With Infusions of Laronidase</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Data was not collected on this outcome measure and is not available for reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Anti-iduronidase Antibodies in Serum</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Improvement in Obstructive Apnea (Breathing) by Polysomnography</measure>
    <time_frame>Baseline, 12 weeks after laronidase, after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Hurler Syndrome</condition>
  <arm_group>
    <arm_group_label>Laronidase ERT Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following</description>
    <arm_group_label>Laronidase ERT Treatment</arm_group_label>
    <other_name>ERT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laronidase ERT</intervention_name>
    <description>Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
    <arm_group_label>Laronidase ERT Treatment</arm_group_label>
    <other_name>AldurazymeÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome)
             who are candidates for first hematopoietic stem cell transplant (HSCT) according to a
             University of Minnesota myeloablative HSCT protocol.

        Exclusion Criteria:

          -  Not being considered for University of Minnesota myeloablative HSCT protocol.

          -  Previous administration of laronidase enzyme

          -  Second or subsequent HSCT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>July 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2019</results_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laronidase ERT</keyword>
  <keyword>Stem cell transplant</keyword>
  <keyword>storage disease</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>hurler syndrome</keyword>
  <keyword>glycosaminoglycans</keyword>
  <keyword>enzyme replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laronidase ERT Treatment</title>
          <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laronidase ERT Treatment</title>
          <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Alive at One Year Post Transplant</title>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at One Year Post Transplant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Requiring Ventilator Support at One Year Post Transplant</title>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Ventilator Support at One Year Post Transplant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Engraftment</title>
        <time_frame>Day 100 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Engraftment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Grade III-IV Acute GVHD</title>
        <time_frame>Day 100 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Grade III-IV Acute GVHD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Glycosaminoglycans (GAG)</title>
        <description>Data was not collected on this outcome measure and is not available for reporting.</description>
        <time_frame>Prior to, During and After ERT</time_frame>
        <population>Data was not collected on this outcome measure and is not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Glycosaminoglycans (GAG)</title>
          <description>Data was not collected on this outcome measure and is not available for reporting.</description>
          <population>Data was not collected on this outcome measure and is not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity (Adverse Events) Associated With Infusions of Laronidase</title>
        <description>Data was not collected on this outcome measure and is not available for reporting.</description>
        <time_frame>1 year post transplant</time_frame>
        <population>Data was not collected on this outcome measure and is not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity (Adverse Events) Associated With Infusions of Laronidase</title>
          <description>Data was not collected on this outcome measure and is not available for reporting.</description>
          <population>Data was not collected on this outcome measure and is not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Anti-iduronidase Antibodies in Serum</title>
        <time_frame>1 Year</time_frame>
        <population>Data was not collected on this outcome measure and is not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Anti-iduronidase Antibodies in Serum</title>
          <population>Data was not collected on this outcome measure and is not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Improvement in Obstructive Apnea (Breathing) by Polysomnography</title>
        <time_frame>Baseline, 12 weeks after laronidase, after transplant</time_frame>
        <population>Data was not collected on this outcome measure and is not available for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Laronidase ERT Treatment</title>
            <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Improvement in Obstructive Apnea (Breathing) by Polysomnography</title>
          <population>Data was not collected on this outcome measure and is not available for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>An SAE as defined by the protocol includes unexpected: 1) laronidase related toxicity which is life threatening, requires hospitalization, causes persistent or significant disability/incapacity, causes congenital anomaly, is a medical event that may jeopardize the patent and require medical/surgical intervention to prevent one of the other outcomes, or causes death; 2) graft failure; 3) severe acute GVHD; and 4) severe regimen related toxicity grade III-IV, which includes mortality.</desc>
      <group_list>
        <group group_id="E1">
          <title>Laronidase ERT Treatment</title>
          <description>Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
Stem Cell Transplant: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERT: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple system organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other, Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Other, Upper respiratory Tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multifocal cerebral infarct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow, NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hemoglobin, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain, Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Necrosis, GI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Liver Function Test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infection, NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infection with Normal Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infection with Unknown Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neurology, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, Ureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mucositis, Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pulmonary, NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vascular, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All of the patients on this trial also underwent allogeneic blood/marrow transplantation. All the serious and non-serious adverse events listed were related to the process of transplantation and not to the study medication, Laronidase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Paul Orchard</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>(612) 626-2313</phone>
      <email>orcha001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

